Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Cellectis S.A. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 31 | 34 | +3 |
| Shares | 11.5M | 9.82M | −1.66M (−14.5%) |
| Value | $18.1M | $30.2M | +$12.1M (+66.7%) |
New holders (9)
Institutions that held Cellectis S.A. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 52,247 | $160.9K | 0.00% |
| Susquehanna International Group, LLP | 19,524 | $60.1K | 0.00% |
| Tennessee Valley Asset Management Partners | 2,430 | $7.48K | 0.00% |
| Baystate Wealth Management LLC | 500 | $1.54K | 0.00% |
| Allworth Financial LP | 500 | $1.54K | 0.00% |
| POM Investment Strategies, LLC | 495 | $1.52K | 0.00% |
| Group One Trading, L.P. | 330 | $1.02K | 0.00% |
| FMR LLC | 40 | $123 | 0.00% |
| Cutler Group LP | 200 | $0 | 0.00% |
Sold out (6)
Institutions that held Cellectis S.A. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Millennium Management LLC | 1,095,966 | $1.73M |
| D. E. Shaw & Co., Inc. | 47,154 | $74.5K |
| TD Waterhouse Canada Inc. | 360 | $540 |
| Tower Research Capital LLC (TRC) | 111 | $175 |
| Barclays PLC | 28 | $44 |
| Royal Bank of Canada | 56 | $0 |